13 patents
Utility
P-ethoxy Nucleic Acids for IGF-1R Inhibition
5 May 22
Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.
Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
Filed: 18 Nov 21
Utility
P-ethoxy Nucleic Acids for STAT3 Inhibition
28 Apr 22
Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a STAT3-encoding polynucleotide.
Ana Tari ASHIZAWA
Filed: 4 Jun 21
Utility
P-ethoxy Nucleic Acids for Liposomal Formulation
25 Nov 21
Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages.
Peter NIELSEN
Filed: 18 Dec 20
Utility
Combination Therapy with Liposomal Antisense Oligonucleotides
26 Aug 21
Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine).
Ana Tari ASHIZAWA
Filed: 15 Jan 21
Utility
P-ethoxy nucleic acids for STAT3 inhibition
22 Jun 21
Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a STAT3-encoding polynucleotide.
Ana Tari Ashizawa
Filed: 19 Apr 18
Utility
P-ethoxy Nucleic Acids for BCL2 Inhibition
29 Apr 21
Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a BCL2-encoding polynucleotide.
Ana Tari ASHIZAWA, Peter NIELSEN
Filed: 19 Apr 18
Utility
P-ethoxy Nucleic Acids for IGF-1R Inhibition
22 Apr 21
Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets an IGF-1R-encoding polynucleotide.
Ana Tari ASHIZAWA
Filed: 19 Apr 18
Utility
Combination therapy with liposomal antisense oligonucleotides
23 Feb 21
Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine).
Ana Tari Ashizawa
Filed: 15 Sep 17
Utility
P-ethoxy nucleic acids for liposomal formulation
26 Jan 21
Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages.
Peter Nielsen
Filed: 30 May 19
Utility
P-ethoxy Nucleic Acids for Liposomal Formulation
15 Apr 20
Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages.
Peter NIELSEN
Filed: 29 May 19
Utility
P-ethoxy Nucleic Acids for IGF-1R Inhibition
5 Feb 20
Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.
Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
Filed: 18 Apr 18
Utility
P-ethoxy Nucleic Acids for STAT3 Inhibition
5 Feb 20
Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a STAT3-encoding polynucleotide.
Ana Tari ASHIZAWA
Filed: 18 Apr 18
Utility
Combination Therapy with Liposomal Antisense Oligonucleotides
29 Jan 20
Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine).
Ana Tari ASHIZAWA
Filed: 14 Sep 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first